Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Grasslanz Technology Limited is active in the Biotechnology & Pharmaceuticals technology area and currently has 2 pending office actions. These matters are distributed across 2 distinct examiners, which provides different perspectives on the company's patent applications. The prosecution is also split between 2 distinct art units, indicating that the technology is being reviewed in different administrative sections of the patent office.
The busiest examiner for this portfolio is MCWILLIAMS, KELSEY LYNN, who is responsible for 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, the workload is evenly divided. This lack of concentration means that the company must adapt to two different examination styles and sets of procedural requirements within the Biotechnology & Pharmaceuticals sector.
Practitioners managing these 2 pending office actions must navigate the specific standards of 2 distinct art units. Because no single examiner handles more than one matter, the portfolio's progress is subject to independent reviews. This distribution reduces the impact of any single examiner's tendencies on the overall portfolio but requires a more varied legal strategy to address the 2 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCWILLIAMS, KELSEY LYNN | 1 | 88.9% | +5.8% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17995191 | INDOLE DITERPENE BIOSYNTHESIS | STEADMAN, DAVID J | 34d |
| 18271400 | Epichloe Endophyte | MCWILLIAMS, KELSEY LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17995191 | INDOLE DITERPENE BIOSYNTHESIS | STEADMAN, DAVID J | 34d |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18271400 | Epichloe Endophyte | MCWILLIAMS, KELSEY LYNN | 1663 | §101§112 | Non-Final OA | — | Pending | Jul 07, 2023 |
| 17995191 | INDOLE DITERPENE BIOSYNTHESIS | STEADMAN, DAVID J | 1656 | §103§112 | Non-Final OA | 34d | Pending | Sep 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial